Trademark: 79349187
Word
DXT
Status
Registered
Status Code
700
Status Date
Tuesday, December 19, 2023
Serial Number
79349187
Registration Number
7245080
Registration Date
Tuesday, December 19, 2023
Mark Type
4000
Filing Date
Tuesday, April 12, 2022
Published for Opposition
Tuesday, October 3, 2023

Trademark Owner History
DOMPE' FARMACEUTICI S.P.A. - Original Registrant

Classifications
9 Downloadable computer software for use in identifying new drugs; downloadable computer software for use by doctors and other medical professionals in capturing, tracking, reporting, analyzing health data for use in making informed medical decisions; downloadable virtual reality software for medical teaching; downloadable virtual reality software for medical screening; downloadable computer software platforms for use in database management in the field of medicine; downloadable computer application software for mobile phones, namely, software for use in identifying new drugs; downloadable computer software using artificial intelligence for use in identifying new drugs; none of the foregoing for use with blood-related cell processing devices, blood-related medical and laboratory devices, blood-related software and technology, or blood-related medical device and data management systems
5 Pharmaceutical preparation for the treatment of respiratory diseases; pharmaceutical preparation for the treatment of bone diseases; analgesic and muscle relaxant pharmaceutical preparations; antibacterial pharmaceuticals; anti-epileptic pharmaceutical preparations; balms for pharmaceutical purposes; capsules sold empty for pharmaceuticals; cardiovascular pharmaceutical preparations; ocular pharmaceuticals; pharmaceutical products for ophthalmological use; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for the prevention and treatment of rare ocular disorders or diseases; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases; pharmaceutical antitussive cold preparations; pharmaceutical preparations for use in chemotherapy; pharmaceutical products for the treatment of viral and infectious diseases; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in the treatment of rare tissue and organ transplantation-related diseases and conditions; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations, namely, anticoagulants; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for peripheral nervous system; pharmaceutical preparations for the treatment of rare diabetes-related conditions; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for the treatment of bacteria-based diseases; pharmaceutical preparations, namely, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations, namely, an analgesic for human consumption taken orally; disinfectants for hygiene purposes; none of the foregoing for use with blood-related cell processing devices, blood-related medical and laboratory devices, blood-related software and technology, or blood-related medical device and data management systems for peripheral nervous system; pharmaceutical preparations for the treatment of rare diabetes-related conditions; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for the treatment of bacteria-based diseases; pharmaceutical preparations, namely, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations, namely, an analgesic for human consumption taken orally; disinfectants for hygiene purposes; none of the foregoing for use with blood-related cell processing devices, blood-related medical and laboratory devices, blood-related software and technology, or blood-related medical device and data management systems
42 Software as a service (SAAS) services featuring software using artificial intelligence for use in identifying new drugs; providing a website featuring non-downloadable software using artificial intelligence for use in identifying new drugs; research in the field of artificial intelligence; design and development of computer software in the field of medicine; design and development of virtual reality software for medical screening; design and development of virtual reality software for medical teaching, none of the foregoing for use with blood-related cell processing devices, blood-related medical and laboratory devices, blood-related software and technology, or blood-related medical device and data management systems

Trademark Events
Mar 29, 2024
Final Disposition Notice Sent To Ib
Mar 29, 2024
Final Disposition Processed
Mar 19, 2024
Final Disposition Notice Created, To Be Sent To Ib
Dec 19, 2023
Notice Of Registration Confirmation Emailed
Dec 19, 2023
Registered-Principal Register
Oct 4, 2023
Notification Processed By Ib
Oct 3, 2023
Official Gazette Publication Confirmation E-Mailed
Oct 3, 2023
Published For Opposition
Sep 13, 2023
Notification Of Possible Opposition Sent To Ib
Sep 13, 2023
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Sep 13, 2023
Notification Of Notice Of Publication E-Mailed
Aug 30, 2023
Approved For Pub - Principal Register
Aug 3, 2023
Teas/Email Correspondence Entered
Aug 3, 2023
Correspondence Received In Law Office
Aug 3, 2023
Teas Response To Office Action Received
Apr 20, 2023
Refusal Processed By Ib
Mar 29, 2023
Non-Final Action Mailed - Refusal Sent To Ib
Mar 29, 2023
Refusal Processed By Mpu
Feb 4, 2023
Non-Final Action (Ib Refusal) Prepared For Review
Feb 3, 2023
Non-Final Action Written
Jan 30, 2023
Assigned To Examiner
Sep 13, 2022
Application Filing Receipt Mailed
Sep 9, 2022
New Application Office Supplied Data Entered
Sep 8, 2022
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24